An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 20 Feb 2018 Planned End Date changed from 31 May 2018 to 1 Jun 2018.
- 20 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 Jun 2018.
- 19 May 2017 Status changed from recruiting to active, no longer recruiting.